title: Plasma levels of amyloid beta 40 and 42 are independent from ApoE genotype and mental retardation in Down syndrome.
abstract: In Down syndrome (DS) brain an early, selective accumulation of amyloid beta (Abeta) peptides ending at residue 42 (Abeta42) occurs. Whether this event depends on an altered processing of amyloid beta precursor protein (APP) or on defective clearance is uncertain. To investigate this issue, we measured Abeta species 40 and 42 in plasma from 61 patients with DS, 77 age-matched normal controls, and 55 mentally retarded subjects without chromosomal abnormalities. The Abeta 40 and 42 plasma levels were then correlated with apolipoprotein E (apoE) genotypes in all groups of cases, and with I. Q. and Mini Mental Status Examination values in DS subjects. Both Abeta species were significantly elevated in DS compared to control groups, and the extent of their increase reflects that expected from APP gene overexpression. Plasma levels of Abeta 40 and 42 did not correlate with apoE genotypes in DS and control cases, and with the extent of mental retardation in DS subjects. The results indicate that accumulation and clearance of plasma and cerebral Abeta are regulated by different and independent factors.
authors: Laboratory of Human Genetics, Galliera Hospital, Genova, Italy.
authors: S
authors: S
authors: Cavani
authors: A
authors: A
authors: Tamaoka
authors: A
authors: A
authors: Moretti
authors: L
authors: L
authors: Marinelli
authors: G
authors: G
authors: Angelini
authors: S
authors: S
authors: Di Stefano
authors: G
authors: G
authors: Piombo
authors: V
authors: V
authors: Cazzulo
authors: S
authors: S
authors: Matsuno
authors: S
authors: S
authors: Shoji
authors: Y
authors: Y
authors: Furiya
authors: D
authors: D
authors: Zaccheo
authors: F
authors: F
authors: Dagna-Bricarelli
authors: M
authors: M
authors: Tabaton
authors: H
authors: H
authors: Mori
mesh_terms: D000293:Adolescent; D000328:Adult; D016229:Amyloid beta-Peptides / Q000009:adverse effects / Q000097:blood*; D016564:Amyloid beta-Protein Precursor / Q000097:blood / Q000378:metabolism; D001057:Apolipoproteins E / Q000235:genetics*; D016022:Case-Control Studies; D002648:Child; D015331:Cohort Studies; D004314:Down Syndrome / Q000097:blood*; D005838:Genotype; D006801:Humans; D008607:Intellectual Disability / Q000097:blood* / Q000209:etiology; D008875:Middle Aged; D010446:Peptide Fragments / Q000009:adverse effects / Q000097:blood; D018709:Statistics, Nonparametric
chemical_list: D016229:Amyloid beta-Peptides; D016564:Amyloid beta-Protein Precursor; D001057:Apolipoproteins E; D010446:Peptide Fragments; C078592:amyloid beta-protein (1-40); C075222:amyloid beta-protein (1-42)